Table of Contents
The term hepatitis means inflammation of the liver, which can be caused by viral, immunologic, bacterial or idiopathic pathology. Viral hepatitis is defined as the inflammation of the liver as a consequence of infection by one of the viral hepatitis viruses. Hepatitis A, B, or C viruses are the most common causes of viral hepatitis. Hepatitis E virus has a similar presentation to hepatitis A while hepatitis D virus is a defective one that is usually superimposed on chronic hepatitis.
Adults infected with hepatitis A or B virus commonly result to having acute viral hepatitis while hepatitis C virus more commonly results in a subclinical acute stage.
Another important definition related to hepatitis is poor hepatic synthetic function, which is defined as a prothrombin time longer than 16 seconds or an international normalized ratio more than 1.5.
Fulminant hepatic failure is a possible complication of acute hepatitis where the patient develops acute liver failure and hepatic encephalopathy.
Acute hepatitis A infection is estimated to affect approximately 25,000 new cases annually. The mode of transmission for hepatitis A virus is fecal-oral and the infection is more common in countries with poor sanitation such as Africa, Asia, and the Middle East.
Hepatitis B infection is more common in the United States with about 43,000 new cases per year. Hepatitis B infection in children is not commonly reported because most cases are asymptomatic. Hepatitis B infection is more common among African Americans with an estimated incidence of 2.3 per 100,000. Chronic hepatitis B is more common in Asians.
Hepatitis B infection can result in chronic hepatitis and eventually liver cirrhosis in about 5 % of the cases. This figure goes significantly higher to about 90% of neonates affected by hepatitis B.
Hepatitis B transmission can happen during the intrapartum period or in utero. Sexual transmission with hepatitis B virus is also common which is through vaginal, rectal and oral-genital intercourse. Approximately, one third of sexual partners of people affected with hepatitis B will also develop the condition. Hepatitis B transmission by blood transfusion is a very uncommon incident nowadays because of the routine screening of donor blood for hepatitis B specific antibodies.
Hepatitis C infection rates are increasing and in 2007 it was estimated that about 17,000 new cases were infected with the virus.
Hepatitis C virus transmission modes are similar to hepatitis B but hepatitis C appears to more prevalent in certain societies. Occupational exposure and intravenous drug abuse are possible risk factors for hepatitis C infection. Hepatitis C virus can also be transmitted sexually but this is less likely to happen as only 5 % of the sexual partners of people with confirmed disease are known to acquire the infection.
Hepatitis D virus is a defective virus that requires the presence of hepatitis B in order for it to replicate. Hepatitis D virus can be superimposed on chronic hepatitis B or can be co-transmitted with hepatitis B in the acute stage.
Finally, hepatitis E virus remains a common cause of acute hepatitis that has a similar mode of transmission to hepatitis A.
Acute viral hepatitis can be caused by hepatitis A, B, C, D, or E viruses in addition to cytomegalovirus, varicella-zoster virus and others. This discuss is focused on the hepatitis specific viruses because other viral pathogens can cause hepatitis as part of a more wide-spread phenomenon rather than specific targeting of the liver.
Hepatitis A and E viruses are usually transmitted via the fecal-oral route. Parenteral transmission via blood transfusion, shared use of needles by drug users, or tattooing is the common route for hepatitis B, C and D transmission.
Sexual activities can put people at risk of acquiring hepatitis B or D and to a much lower extent hepatitis C. Hepatitis B transmission during delivery or in utero is common. Finally, sporadic cases of hepatitis B and C are common but the most likely cause for these sporadic cases is in fact sexual transmission.
Hepatitis A, C, D, and E viruses are RNA viruses. On the other hand, hepatitis B virus is unique because it is a DNA virus.
Hepatitis A virus has an incubation period of two to four weeks. Viral transmission is possible in the first few weeks before the onset of symptoms. Hepatitis A virus infection is associated with elevated alkaline phosphatase levels. Patients infected with hepatitis A are at risk of developing fulminant hepatic failure.
Hepatitis B infection is classified into acute and chronic stages. The incubation period for hepatitis B virus is usually 12 weeks and once the symptoms start in the acute stage they are usually mild. Serum levels of hepatitis B viral DNA are usually elevated in the acute stage and patients are at first in the immune-tolerant phase. During this phase, alanine aminotransferase levels are usually normal but HBeAg, a marker for viral replication, is usually positive.
In some cases, HBeAg becomes negative. These people enter the inactive carrier state in which viral replication and transmission are minimum. People within the inactive carrier state can still transmit the virus sexually or via blood transfusion. People who enter this state might develop chronic hepatitis, which is marked by elevated liver enzymes and liver damage on biopsy.
In the chronic stage of hepatitis B infection, people are usually tired. At this stage, hepatic dysfunction becomes evident by the presence of extrahepatic manifestation of liver disease. Liver enzymes are usually elevated, HbeAg is positive indicating active viral replication, and liver biopsy shows inflammation and fibrosis.
Extensive fibrosis of the liver eventually leads to liver cirrhosis and hepatic failure. It is clear from this pathophysiologic overview of hepatitis B disease that the immune response plays an important role in repeated liver injury and repair. People who develop chronic hepatitis B are at risk of developing hepatocellular carcinoma.
Hepatitis C has an incubation period of 8 weeks. People in the acute stage usually have mild elevations of hepatic aminotransferases. The risk of chronic hepatitis from infection with hepatitis C virus is markedly higher compared to other hepatitis viruses. If the patient enters the chronic stage, it usually takes 10 years until they develop liver cirrhosis.
Hepatitis D virus can be superimposed on a cirrhotic liver that is already infected with hepatitis B. If this happens, patients develop a flare of their disease and might develop fulminant hepatic failure.
Hepatitis E virus has an incubation period of 2 to 9 weeks. Aminotransferases might be elevated in hepatitis E in contrast to hepatitis A. Pregnant women infected with hepatitis E virus are at a significant risk of mortality due to fulminant hepatic failure.
- HAV does NOT cause chronic hepatitis.
- Prolonged hepatocellular necrosis and inflammation for >6 months
- HBV, HCV, HBV-associated HDV, HEV
- HEV only in immunosuppressed patients
Regardless of the exact etiology of viral hepatitis, the symptoms of the disease can be classified into four main stages.
- In phase 1 of the disease, patients are asymptomatic but viral replication is happening. During this stage, laboratory investigations and liver chemistry can detect subclinical hepatitis.
- In phase 2 of the disease, patients enter the prodromal phase. During this phase, patients develop non-specific symptoms that include nausea, vomiting, anorexia, fatigue, and pruritus.
- Phase 3 is characterized by jaundice, dark urine, and pale-colored stools. At this stage, patients might develop upper gastrointestinal pain that is more localized to the right side. At this stage, the physician usually makes the diagnosis of acute hepatitis.
- In phase 4, patients enter the convalescent phase. During this stage, symptoms of acute illness resolve. Depending on the infecting viral pathogen, patients might develop an inactive carrier stage, develop active chronic hepatitis, or their condition might completely resolve.
Based on the clinical picture and the most likely mode of transmission, one can suspect whether the patient is infected with hepatitis A, or B and C viruses. Accordingly, the different diagnostic workup modalities will differ depending on the most likely causative virus.
If hepatitis A is the most likely cause, patients can undergo serum testing of IgM antibodies against hepatitis A virus which happen in the acute stage. IgG antibodies are usually present in people who were previously infected by hepatitis A virus but are not useful in the acute stage.
People infected with hepatitis B virus first show a positive HbsAg, which is defined as hepatitis B surface antigen. HbeAg can also be present in the acute stage and is a marker of viral replication. People can then enter the inactive carrier stage once HBeAg become negative and anti-HBe antibodies become positive.
In the acute stage, antibodies against the core antigen of hepatitis B virus can be identified. These are usually IgM antibodies that can be used to diagnose acute hepatitis B infection. If the patient develops complete clearance of hepatitis B, anti-HBs antibodies become positive. This usually happens 4 to 6 months after acquiring the infection.
People infected with hepatitis C virus benefit from liver chemistry testing, hepatitis C virus RNA polymerase chain reaction testing and liver biopsy.
Patients with hepatitis B disease who suddenly develop a worsening of their symptoms might have acquired hepatitis D. IgM anti-HDV antibodies are useful in detecting acute superimposed infection with hepatitis D. Hepatitis E virus can be identified by RNA testing or by the detection of IgM anti-HEV antibodies.
Treatment of acute hepatitis A is mainly symptomatic. Patients are at risk of developing dehydration and adequate fluid replacement therapy is indicated.
Patients with acute hepatitis B virus benefit from supportive treatment but specific antiviral therapy might also be useful. Lamivudine and adenofovir dipivoxil have been used in the acute stage and shown to lower the risk of developing inactive carrier state or chronic hepatitis B.
Patients who develop chronic hepatitis B should receive interferon therapy. Interferon alpha might be beneficial in the treatment of chronic hepatitis B. Lamivudine inhibits DNA polymerase-associated reverse transcriptase which is found in hepatitis B virus particles. Due to this effect, lamivudine can prevent or suppress hepatitis B virus replication.
Adefovir dipivoxil is another DNA polymerase inhibitor that has been used with excellent results in hepatitis B chronic state. Entecavir is another antiviral approved for the treatment of hepatitis B with viral clearance rates of 60% in people who are HBeAg positive and 90% in patients with HBeAg negative state.
Patients with acute hepatitis C are rarely identified. If the patient is confirmed to have acute hepatitis C, interferon alpha therapy should be initiated. People who develop chronic hepatitis C should receive interferon alpha-2b or 2a combined with ribavirin. New drugs are being approved for the treatment of hepatitis C.
Treatment of superimposed hepatitis D is not well established yet. Supportive treatment of hepatitis E and close monitoring of pregnant women is indicated to detect people who develop fulminant hepatic failure. Liver transplantation might be needed in patients with fulminant hepatic failure.